Olaparib for treating BRCA mutation-positive HER2-negative advanced breast cancer after chemotherapy

Olaparib (Lynparza, AstraZeneca) is indicated as 'monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR) positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy'.

The dosage schedule is available in the summary of product characteristics for olaparib.

The list price of olaparib is £2,317.50 per 56 pack of 150-mg tablets (excluding VAT, BNF online, accessed October 2024).

The company has a confidential commercial access agreement with NHS England. As part of this agreement, olaparib is available to the NHS with a discount. The size of the discount is commercial in confidence.